Construction of a core-shell microneedle system to achieve targeted co-delivery of checkpoint inhibitors for melanoma immunotherapy

Yang, Peipei; Lü, Chao; Qin, Wanbing; Chen, Minglong; Quan, Guilan; Hu, Liu; Wang, Lili; Bai, Xuequn; Pan, Xin; Wu, Chuanbin

doi:10.1016/j.actbio.2019.12.037

Cited by 84 publications

(40 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The limitations include low drug loading capacity owing to the small volume of their microstructures and the inability of simultaneous multi-drug loading due to the specific interaction of drug-matrix [104,105]. To overcome some of these disadvantages, Yang et al fabricated a highly drugconcentrated hybrid core-shell MN (CSMN) system to facilitate the co-delivery of checkpoint inhibitors, 1-MT and aPD-L1, into the TME (Figure 4A and 4B) [106]. The author firstly synthesized the shell of CSMN by pipetting sodium alginate and chitosan solution onto the surface of a polydimethylsiloxane (PDMS) mold, followed by the addition of aPD-L1.…”

Section: Design Of Mns For Cancer Immunotherapy By Pd-l1 Blockadementioning

confidence: 99%

Microneedles for painless transdermal immunotherapeutic applications

Amani

Shahbazi

D'Amico

et al. 2021

Journal of Controlled Release

146

View full text Add to dashboard Cite

This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article. Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

show abstract

Section: Design Of Mns For Cancer Immunotherapy By Pd-l1 Blockadementioning

confidence: 99%

Microneedles for painless transdermal immunotherapeutic applications

Amani

Shahbazi

D'Amico

et al. 2021

Journal of Controlled Release

146

View full text Add to dashboard Cite

show abstract

“…Microneedle patches that consist of miniaturized needles, generally 100–1000 μm in length, have emerged as promising tools for bypassing the skin stratum corneum barrier and effectively delivering therapeutic agents into deep skin layers in a minimally invasive manner 280 , 281 . Therefore, microneedle-mediated transdermal delivery is a viable option for promoting the transdermal delivery of MDPs to combat skin infections and cancer 282 , 283 , 284 , 285 . Recently, Xie's group 286 reported a fabricated Janus-type antimicrobial dressing, consisting of AMP-loaded electrospun nanofiber membranes and dissolvable microneedle arrays, for the eradication of biofilms in chronic wounds.…”

Section: Mdps-based Formulations and Their Applicationsmentioning

confidence: 99%

Membrane-disruptive peptides/peptidomimetics-based therapeutics: Promising systems to combat bacteria and cancer in the drug-resistant era

Lin

Chi

Yan

et al. 2021

Acta Pharmaceutica Sinica B

Self Cite

View full text Add to dashboard Cite

Membrane-disruptive peptides/peptidomimetics (MDPs) are antimicrobials or anticarcinogens that present a general killing mechanism through the physical disruption of cell membranes, in contrast to conventional chemotherapeutic drugs, which act on precise targets such as DNA or specific enzymes. Owing to their rapid action, broad-spectrum activity, and mechanisms of action that potentially hinder the development of resistance, MDPs have been increasingly considered as future therapeutics in the drug-resistant era. Recently, growing experimental evidence has demonstrated that MDPs can also be utilized as adjuvants to enhance the therapeutic effects of other agents. In this review, we evaluate the literature around the broad-spectrum antimicrobial properties and anticancer activity of MDPs, and summarize the current development and mechanisms of MDPs alone or in combination with other agents. Notably, this review highlights recent advances in the design of various MDP-based drug delivery systems that can improve the therapeutic effect of MDPs, minimize side effects, and promote the co-delivery of multiple chemotherapeutics, for more efficient antimicrobial and anticancer therapy.

show abstract

“…[ 75 ] To this end, Wu's team developed a core‐shell microneedle (CSMN) system for the codelivery of aPD‐L1 and 1‐MT with increased drug loading (Figure 4E). [ 74 ] The charged chitosan (CS) shell layer could adsorb aPD‐L1 through strong electrostatic interaction to reduce its diffusion during the preparation process, and concentrate it on the tips of the microneedles. The core of the microneedles was comprised of polyvinyl alcohol (PVA) and other polymers rich in hydrogen bond donors and acceptors, which could form hydrogen bonds with 1‐MT to inhibit the premature crystallization of 1‐MT and maintain its concentration in supersaturated state.…”

Section: Synergistic Tumor Treatment Based On Immune Checkpoint Blockade Therapymentioning

confidence: 99%

“…F) CD3 + T cells and G) CD3 + CD8 + T cells per 10 000 of cells in tumor tissue (red blood cells removed)12 days after treatment with CSMN (Mean ± SD, n = 3). E-G) Reproduced with permission [74]. Copyright 2020, Elsevier.…”

mentioning

confidence: 99%

Immune Checkpoint Inhibitor‐Based Strategies for Synergistic Cancer Therapy

Yang

Wang

et al. 2021

Adv Healthcare Materials

View full text Add to dashboard Cite

Immune checkpoint blockade therapy (ICBT) targeting checkpoints, such as, cytotoxic T‐lymphocyte associated protein‐4 (CTLA‐4), programmed death‐1 (PD‐1), or programmed death‐ligand 1 (PD‐L1), can yield durable immune response in various types of cancers and has gained constantly increasing research interests in recent years. However, the efficacy of ICBT alone is limited by low response rate and immune‐related side effects. Emerging preclinical and clinical studies reveal that chemotherapy, radiotherapy, phototherapy, or other immunotherapies can reprogramm immunologically “cold” tumor microenvironment into a “hot” one, thus synergizing with ICBT. In this review, the working principle and current development of various immune checkpoint inhibitors are summarized, while the interactive mechanism and recent progress of ICBT‐based synergistic therapies with other immunotherapy, chemotherapy, phototherapy, and radiotherapy in fundamental and clinical studies in the past 5 years are depicted and highlighted. Moreover, the potential issues in current studies of ICBT‐based synergistic therapies and future perspectives are also discussed.

show abstract

Construction of a core-shell microneedle system to achieve targeted co-delivery of checkpoint inhibitors for melanoma immunotherapy

Cited by 84 publications

References 31 publications

Microneedles for painless transdermal immunotherapeutic applications

Microneedles for painless transdermal immunotherapeutic applications

Membrane-disruptive peptides/peptidomimetics-based therapeutics: Promising systems to combat bacteria and cancer in the drug-resistant era

Immune Checkpoint Inhibitor‐Based Strategies for Synergistic Cancer Therapy

Contact Info

Product

Resources

About